. Author manuscript; available in PMC: 2018 Mar 8.

Published in final edited form as: Cell Oncol (Dordr). 2016 Sep 27;40(1):1–20. doi: 10.1007/s13402-016-0297-1

Table 1.

A snapshot of therapeutic approaches aiming at leukemic stem cells that are available for the management of hematological malignancies

Target	Compound	References
Cell surface antigens	Gemtuzumab, DT₃₈₈IL3, 7G3 antibody, H90 antibody, Dacluzumab, B6H12.2 or BRIC 126, 21.16 and 1075.7, αCLL1-αCD3, 81.2 antibody	[13, 27, 33, 39, 40, 44–46, 160]
Differentiation therapies	ATRA, DFO, DFX, EP, Sabutoclax	[48, 53, 54]
Mitochondria and metabolic pathways	Sabutoclax, MEK inhibitor with ABT-737, obutoclax with sorafenib, tigecycline, PKM2	[59–63, 66, 67]
Epigenetic regulators	VAL-AZA, DOT1L, LSD1, EZH2, IDH1/2, Menin, Brd4, menin-MLL inhibitors, LSD1 inhibitors, DZNep	[73–78, 80–82, 161]
Cell signaling pathways	PTL, DMAPT, Celastrol, 4-HNE, AR42, AS602869, LY29402, VP16, Wortmannin, Perifosine, Sirolimus, etoposide, clofarabine, NVP-BEZ235, GDC-0980, XL-765	[86, 90, 92, 94, 98, 99, 102, 105, 106, 110–112]
Reactive oxigen species	PTL, piperolongumine, DZNep, AF, Fenretinide, Deferaxirox	[53, 82, 90, 117, 119]
Heat shock proteins	17-AAG, 17-DMAG, PU-H71	[124–127]
Self renewal pathways	Hydrazones, Homoharringtonine, AV65, Indometacin, GSI, cyclopamine	[9, 137, 138, 140, 142]
Microenvironment disruptions	Perixafor, neutralizing CXCR4 or CXCL12 antibodies, AMD3465, echinomycin, E-selectin ligand	[5, 149–151]